Summary:
- Volume Zscore is a recent 2 week high. A recent surge of ZScore means trading activities is accelerating at a record speed.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) * 10X Genomics Inc (NASDAQ: TXG) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Beigene Ltd (NASDAQ: BGNE) * Cardiff Oncology Inc (NASDAQ: CRDF) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Evogene Ltd (NASDAQ: EVGN) * Fate Therapeutics Inc (NASDAQ: FATE) * Guardant Health Inc (NASDAQ: GH) * InVitae Corp (NYSE: NVTA) * Kaleido Bioscienc...
BOSTON and LONDON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the following virtual investor conferences in September: * Morgan Stanley 18th Annual Global Healthcare Conference on September 18, 2020 at 8:45 AM ET * Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020 at 9:10 AM ETLive webcasts of each presentation will be available under "New...
Data on all eight patients demonstrate sustained engraftment and supranormal IDUA enzyme expression Translation of metabolic correction to clinical outcomes in first two patients continues to support potential of hematopoietic stem cell gene therapy in a second neurometabolic disorderData support planned initiation of registrational trial in 2021BOSTON and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced additional int...
Shares of Orchard Therapeutics (NASDAQ: ORTX) are up by 16.9% as of 12:27 p.m. EDT on Tuesday after rising by as much as 32.9% earlier today. The biotech company did not report any news that served as a catalyst for these massive gains, though, so what gives? Orchard Therapeutics' stock was down by more than 60% year to date before today, and perhaps investors who finally felt as though the price was right bid up the company's shares.
In times like these, investors can get by with a little help from the Wall Street legends. Deemed as “the man who solved the market,” Jim Simons relied on his experience as a mathematician and code-breaker to pioneer a ground-breaking investing approach, one that involved crunching data and developing predictive algorithms.Founding one of the most formidable hedge funds on the Street, Renaissance Technologies, in 1978, Simons, who is worth approximately $23 billion, has more than earned his repu...
BOSTON and LONDON, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced presentations at the upcoming 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), taking place virtually from August 29 - September 1, 2020. New interim data from OTL-203, an investigational gene therapy for the treatment of mucopolysaccharidosis type I (MPS-I), will be shared as part of an invited oral presentation titled ‘G...